Retroviral vectors have been constructed that express one or more of the following gene products: sCD4 (or it's derivatives), alpha-interferon, transdominant rev mutants, and an HIV inducible diphtheria toxin. The goal of this work is to engineer human lymphocytes such that they manifest anti-HIV activity and thus may prevent HIV infection or decrease viral replication. Initial work has concentrated on construct retroviral vectors that produce a secreted form of the helper/inducer T-cell antigen, CD4 (sCD4). It has been demonstrated by cocultivation that transduced cells (producing sCD4) can protect HIV susceptible cell from infection by HIV. Further , it was shown that sCD4 transduced primary human lymphocytes can be directly protected from HIV infection. All of these anti-HIV systems are currently being tested in AIDS animal models, specifically, Hu-PBL-SCID mice.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Intramural Research (Z01)
Project #
1Z01HL002218-03
Application #
3858036
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
National Heart, Lung, and Blood Institute
Department
Type
DUNS #
City
State
Country
United States
Zip Code